BARcure
Novel Therapeutic Approach for the Treatment of B-cell Malignancies
Company Overview
Snapshot
Founded in June 2017, BARcure operates with 1–10 employees. The company ceased operations in April 2019.
Business overview
BARcure is a Health Tech & Life Sciences company focused on developing novel therapeutic approaches for B-cell malignancies, primarily non-Hodgkin's lymphoma (NHL). The company's core technology involves immunotherapies designed to specifically target and eliminate malignant B cells while preserving normal B cells. BARcure is currently concentrating on two BAR-based products for treating DLBCL and MCL, leveraging research from Saarland University in Germany. It operates within the pharmaceuticals, immunology, and oncology sectors, serving the healthcare and life sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is BARcure's primary focus?
- BARcure focuses on developing novel therapeutic approaches for B-cell malignancies, with a primary emphasis on non-Hodgkin's lymphoma (NHL).
- What is BARcure's core technology?
- BARcure's core technology involves developing immunotherapies that specifically target malignant B cells, aiming to eliminate tumor cells while sparing normal B cells.
- When was BARcure founded?
- BARcure was founded in June 2017.
- What is the operational status of BARcure?
- BARcure ceased operations in April 2019.
- Which markets does BARcure target?
- BARcure targets the healthcare and life sciences markets, specifically within the pharmaceuticals, immunology, and oncology sectors.